Welcome to the new Regeneron Newsroom. This newsroom is designed to provide members of the media with easy access to up-to-date information about the Company. If you are a reporter with a question about Regeneron, please call our Media Line at (914) 345-7800.
For an e-mail response to questions about Regeneron, please contact us at media@regeneron.com.
Click on this photo of Len Schleifer to listen to Len’s remarks from Regeneron’s October 6 public ribbon cutting event.
| Recent Events |
| Aug 13, 2010 |
Bank of America Merrill Lynch 2010 Specialty Pharmaceuticals Conference
 View Presentation
|
| Jul 15, 2010 |
Regeneron 2010 Investor Day
Note: These videos were shown at the meeting but not webcast.
You may view them here at any time.
 VelociGene® and VelocImmune® Technologies: A Brief History
Process Development and Manufacturing
Introduction: Leonard Schleifer, M.D., Ph.D., Chief Executive Officer
R&D Overview: George Yancopoulos, M.D., Ph.D., Chief Scientific Officer
Early Clinical Development: Neil Stahl, Ph.D., Senior Vice President, Research and Development Sciences
Early Stage Development: Peter Powchik, M.D., Senior Vice President, Clinical Development
Oncology: Alain Thibault, M.D., Vice President, Clinical Sciences, Oncology
VEGF Trap–Eye: Robert Vitti, M.D., Executive Director, Clinical Sciences, Ophthalmology
ARCALYST® (rilonacept): Bob Terifay, Senior Vice President, Commercial
Financial Overview: Murray Goldberg, Chief Financial Officer
Industrial Operations and Product Supply: Dan Van Plew, Senior Vice President, Industrial Operations and Product Supply
Conclusion: Leonard Schleifer, M.D., Ph.D., Chief Executive Officer
|
| Jun 16, 2010 |
Goldman Sachs 31st Annual Global Healthcare Conference
|
|
